ArticleSleep & breathing = Schlaf & Atmung2025
Effect of obstructive sleep apnea risk on sialorrhea in patients with Parkinson's disease.
Article in Sleep & breathing = Schlaf & Atmung, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOur aim was to determine the effect of obstructive sleep apnea syndrome (OSAS) risk on sialorrhea in patients with Parkinson's disease (PD).
methodsA total of 75 patients with PD (mean age 66.36 ± 8.07) were included. Sialorrhoea was evaluated using the "Sialorrhoea Clinical Scale for Parkinson's Disease" and OSAS risk was determined using the STOP-Bang questionnaire. Diurnal and nocturnal sialorrhoea, drooling severity, speech impairment, eating impairment frequency of drooling, and social discomfort were evaluated. Patients were classified as having low, moderate, or high risk of OSAS. One-way analysis of variance, Tukey's multiple comparison test, Kruskal-Wallis test, Bonferroni-Dunn tests, and Fischer's exact test were used to compare groups according to the normality of the data.
resultsPatients were classified as low risk (n = 10), intermediate risk (n = 29) and high risk (n = 36). The clinical characteristics were similar in all risk groups. The highest rate of nocturnal sialorrhea was observed in all risk groups. The lowest-risk group scored 4.30 ± 3.09, whereas the intermediate- and high-risk groups scored 4.21 ± 4.46, 6.94 ± 4.81 respectively for sialorrhea (p = 0.034). A significant difference in sialorrhea between the groups was found in the intermediate and high-risk groups (p = 0.034).
conclusionThis study showed that sialorrhea changes were significant in patients with PD in the intermediate-and high-risk OSAS groups. It may be suggested that sialorrhoea be assessed and included in the treatment program in patients at high risk of OSAS or that PD patients with high levels of sialorrhoea should be tested for OSAS. Patients may benefit from treatment methods that address both conditions.
Indexed as
Identifiers
39776271What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.